PRODUCT INFORMATION



Gypenoside XVII

Item No. 34514

CAS Registry No.:	80321-69-3	\ \	
Formal Name:	3β-(β-D-glucopyranosyloxy)-12β-	\geq	
	hydroxydammar-24-en-20-yl 6-O-β-D-	/ ОН	
	glucopyranosyl-β-D-glucopyranoside	, t	Н ДН СОН
Synonyms:	Gyp-17, Gyp-XVII, Gynosaponin S	он	
MF:	C ₄₈ H ₈₂ O ₁₈	но	ОН ТОН
FW:	947.2	Ĥ	
Purity:	≥98%	HO	но
Supplied as:	A solid	й Ли	\sum
Storage:	-20°C		но
Stability:	≥4 years		НО
Item Origin:	Plant/Gynostemma pentaphyllum		HO

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Gypenoside XVII is supplied as a solid. A stock solution may be made by dissolving the gypenoside XVII in the solvent of choice, which should be purged with an inert gas. Gypenoside XVII is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of gypenoside XVII in these solvents is approximately 5 and 10 mg/ml, respectively.

Gypenoside XVII is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, gypenoside XVII should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Gypenoside XVII has a solubility of approximately 0.2 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Gypenoside XVII is a saponin that has been found in P. notoginseng and has diverse biological activities.¹⁻⁴ It induces autophagic clearance of amyloid- β precursor protein (APP), A β 40, and A β 42 in PC12 cells expressing Swedish mutant APP isoform 695 (APP695 Swe) when used at a concentration of 10 μ M.¹ Gypenoside XVII (40 mg/kg) prevents the formation of hippocampal and cortical A β plaques and ameliorates spatial cognitive deficits in the transgenic APP/PS1 mouse model of Alzheimer's disease. It decreases lipid deposition in the aortic sinus and serum levels of malondialdehyde (MDA), reduces aortic plaque area, and increases serum levels of superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase in ApoE^{-/-} mice.² Gypenoside XVII (10 and 50 mg/kg) reduces spinal cord edema and neuronal apoptosis in a mouse model of mechanical compression-induced spinal cord injury.³ It also maintains retinal permeability and structure and reduces retinal levels of apoptotic proteins in a db/db mouse model of early diabetic retinopathy.⁴

References

- 1. Meng, X., Luo, Y., Liang, T., et al. J. Alzheimers Dis. 52(3), 1135-1150 (2016).
- 2. Yang, K., Zhang, H., Luo, Y., et al. Int. J. Mol. Sci. 18(2), 77 (2017).
- 3. Sun, T., Duan, L., Li, J., et al. Int. J. Mol. Med. 48(2), 146 (2021).
- 4. Luo, Y., Dong, X., Lu, S., et al. Eur. J. Pharmacol. 895, 173893 (2021).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM